IP Library Granted Patent US 10,137,245
Granted Patent B2
US 10,137,245 · App. 13/817,156 · Granted Nov 27, 2018

Central site photoplethysmography, medication administration, and safety

Inventors: Richard J. Melker (Gainesville, FL); Donn M. Dennis (Gainesville, FL); Jeremy Melker (Gainesville, FL); Mark Rice (Gainesville, FL); Robert Hurley (Gainesville, FL); Mark Gold (Alachua, FL); Richard Allen (Gainesville, FL)
Assignee: University of Florida Research Foundation, Inc.
A61M5/1723A61B5/0205A61B5/14551A61B5/4839A61B5/6803A61M16/00A61M16/0051A61M16/026A61M16/0666A61M16/0677A61M16/10A61M16/161G06F19/00G06F19/3456G06F19/3468A61B5/002A61B5/024A61B5/0402A61B5/0816A61B5/0826A61B5/0836A61B5/4818A61B5/4821A61B5/7246A61M2005/16863A61M2016/0027A61M2205/3368A61M2230/04A61M2230/205A61M2230/432
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,137,245
App. No.
13/817,156
Granted
Nov 27, 2018
Kind
B2
Abstract

A monitoring and control system, apparatus and method for safe administration, reduction or cessation of administration of at least on medication, fluid or both, which includes at least one Central Source Site (CSS) Photoplethysmography (PPG) sensor coupled to means for control of delivery of the at least one medication, fluid or both.

Claims (15)

1. A system for monitoring and control for safe administration, reduction or cessation of administration of at least one of medication to a subject, comprising:

(a) at least one photoplethysmography (PPG) sensor adapted to secure to a central source site of the subject;

(b) an infusion pump for delivering the at least one medication to the subject, wherein the infusion pump comprises an infusion controller for increasing or decreasing flow of medication to the subject; and

(c) an infusion pump agnostic safety device that is adapted to be deployed onto tubing adapted to deliver the at least one medication from the infusion pump to the subject, wherein the safety device comprises an occlusion apparatus and an occlusion controller, wherein the occlusion controller receives signals from the PPG sensor, calculates at least one respiratory parameter based on the signals from the PPG sensor, and if the at least one respiratory parameter is determined by the occlusion controller to be adverse, the occlusion controller directs the occlusion apparatus to partially or completely occlude the tubing

wherein the infusion pump agnostic safety device only occludes the tubing in the event the occlusion controller determines that an adverse event has occurred.

2. The system of claim 1 , wherein the at least one respiratory parameter comprises respiratory rate, respiratory effort, or both.

3. The system of claim 1 , wherein the occlusion controller is further configured to initiate an alarm if the at least one respiratory parameter is determined by the occlusion controller to be adverse.

4. The system of claim 1 , further comprising at least one additional sensor.

5. The system of claim 4 , wherein the at least one additional sensor is selected from the group consisting of an electrocardiograph, a capnometer, a nasal pressure sensor and a nasal flow sensor.

6. The system of claim 4 , wherein the occlusion controller sends signals to the occlusion apparatus to partially or completely occlude the tubing if an adverse parameter based on signals from the at least one additional sensor is detected.

7. The system of claim 1 , wherein the infusion pump is a patient controlled anaesthesia (PCA) pump.

8. The system of claim 1 , wherein the medication comprises at least one of an opioid, a benzodiazepine and propofol.

9. The system of claim 1 , further comprising ventilation means for applying positive ventilation pressure to the subject upon receipt by the ventilation means of a control signal to initiate, increase or decrease ventilation.

10. The system of claim 9 , wherein the control signal to initiate, increase or decrease ventilation is given to the ventilation means from the occlusion controller when at least one adverse respiratory parameter is determined by the controller.

11. The system of claim 1 , wherein the central source site of the individual is the nasal septum or the nasal alar.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2018
From: XHALE, INC.
To: XHALE ASSURANCE, INC.
Reel/Frame 047471/0260 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2013
From: MELKER, RICHARD J.; DENNIS, DONN M.; RICE, MARK; HURLEY, ROBERT; GOLD, MARK S.
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 030325/0940 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2013
From: MELKER, JEREMY; ALLEN, RICHARD
To: XHALE, INC.
Reel/Frame 030326/0100 →
Continuity (4)
Provisional Application 61374597 · Aug 17, 2010
Provisional Application 61438620 · Feb 1, 2011
Provisional Application 61441621 · Feb 10, 2011
Related Publication 20130276785A1 · Oct 24, 2013
Cited By (56)
US 12,193,636 US 12,193,766 US 12,207,817 US 12,226,151 US 12,226,166 US 12,228,987 US 12,232,729 US 12,233,241 US 12,235,697 US 12,239,320 US 12,239,353 US 12,256,995 US 12,293,432 US 12,295,674 US 12,303,159 US 12,310,586 US 12,315,036 US 12,318,152 US 12,329,437 US 12,329,467 US 12,354,186 US 12,364,683 US 12,369,960 US 12,369,994 US 12,376,855 US 12,376,896 US 12,383,115 US 12,396,806 US 12,397,104 US 12,433,508 US 12,444,094 US 12,458,351 US 12,462,439 US 12,488,512 US 12,493,996 US 12,500,948 US 12,505,584 US 12,514,584 US 12,521,191 US 12,549,622 US 12,574,434 US 12,575,855 US 12,582,457 US 12,594,377 US 12,629,194 US 12,639,250 US 12,648,789 US 12,653,628 US 12,653,947 US 12,661,188 US 12,670,670 US 12,672,922 US 12,682,578 US 12,682,579 US 12,697,178 US 12,708,427